ID   Onda 10
AC   CVCL_3075
SY   Onda-10; no.10; no-10; NO10; Case 6
DR   CLO; CLO_0009898
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 968
DR   BioSample; SAMN03472789
DR   cancercelllines; CVCL_3075
DR   Cell_Model_Passport; SIDM00574
DR   CGH-DB; 151-1
DR   ChEMBL-Cells; CHEMBL3308838
DR   ChEMBL-Targets; CHEMBL2366071
DR   Cosmic; 687579
DR   Cosmic; 908452
DR   Cosmic; 2367541
DR   Cosmic-CLP; 908452
DR   DepMap; ACH-001605
DR   EGA; EGAS00001000978
DR   GDSC; 908452
DR   GEO; GSM1670281
DR   IARC_TP53; 21593
DR   IARC_TP53; 23809
DR   JCRB; IFO50368
DR   JCRB; JCRB1606
DR   LINCS_LDP; LCL-1386
DR   PharmacoDB; no10_1163_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_3075
DR   RCB; RCB4499
DR   Wikidata; Q54936400
RX   CelloPub=CLPUB00089;
RX   PubMed=3188836;
RX   PubMed=8878451;
RX   PubMed=10551321;
RX   PubMed=16232199;
RX   PubMed=18415661;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8878451).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.63%; Native American=0.27%; East Asian, North=79.08%; East Asian, South=19.61%; South Asian=0%; European, North=0.4%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Brain, left parietal lobe; UBERON=UBERON_0002802.
ST   Source(s): Cosmic-CLP; DepMap; JCRB
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 12
ST   D16S539: 11
ST   D18S51: 15,17
ST   D21S11: 29,32.2
ST   D3S1358: 15,17
ST   D5S818: 12,13
ST   D7S820: 8,11
ST   D8S1179: 13,16
ST   FGA: 23
ST   Penta D: 10,14
ST   Penta E: 16
ST   TH01: 7,9
ST   TPOX: 9
ST   vWA: 17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   CelloPub=CLPUB00089;
RA   Onda K., Washiyama K., Tanaka R., Nishiyama A., Usui H., Kumanishi T.;
RT   "GFAP-positive human glioma cell lines: no.11, no.10.";
RL   Hum. Cell 3:251-252(1990).
//
RX   PubMed=3188836; DOI=10.1007/BF00686381;
RA   Onda K., Tanaka R., Washiyama K., Takeda N., Kumanishi T.;
RT   "Correlation of DNA ploidy and morphological features of human glioma
RT   cell cultures with the establishment of cell lines.";
RL   Acta Neuropathol. 76:433-440(1988).
//
RX   PubMed=8878451; DOI=10.1111/j.1349-7006.1996.tb02118.x;
RA   Zhang S., Endo S., Koga H., Ichikawa T., Feng X., Onda K.,
RA   Washiyama K., Kumanishi T.;
RT   "A comparative study of glioma cell lines for p16, p15, p53 and p21
RT   gene alterations.";
RL   Jpn. J. Cancer Res. 87:900-907(1996).
//
RX   PubMed=10551321; DOI=10.1111/j.1349-7006.1999.tb00838.x;
RA   Zhang S.-J., Endo S., Ichikawa T., Yoshimura J., Onda K., Tanaka R.,
RA   Washiyama K., Kumanishi T.;
RT   "Rare-type mutations of MMAC1 tumor suppressor gene in human glioma
RT   cell lines and their tumors of origin.";
RL   Jpn. J. Cancer Res. 90:934-941(1999).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=18415661; DOI=10.1007/s10014-007-0226-0;
RA   Tanaka Y., Zhang S.-J., Terasaki H., Koga H., Endo S., Usui H.,
RA   Washiyama K., Kumanishi T., Uematsu Y., Itakura T.;
RT   "Frequent and variable abnormalities in p14 tumor suppressor gene in
RT   glioma cell lines.";
RL   Brain Tumor Pathol. 25:9-17(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//